Joseph A. Gogos, MD, PhD

  • Professor of Physiology and Cellular Biophysics, Neuroscience and Psychiatry (in the Mortimer B. Zuckerman Mind Brain Behavior Institute)
Profile Headshot

Overview

Dr. Joseph A. Gogos has made pioneering contributions to uncovering the biological foundations of schizophrenia and other psychiatric disorders, including landmark discoveries of rare inherited and de novo genetic variants that confer substantial disease risk. His work bridges human genetics, molecular and cellular biology, and experimental models to reveal how genetic and other biological disruptions affect brain development, neural circuits, and behavior, while identifying new therapeutic opportunities. As Co-Director of Columbia University's Stavros Niarchos Foundation Center for Precision Psychiatry & Mental Health, he is helping advance a more integrated, biology-driven approach to the prevention, diagnosis, and treatment of mental illness.

Academic Appointments

  • Professor of Physiology and Cellular Biophysics, Neuroscience and Psychiatry (in the Mortimer B. Zuckerman Mind Brain Behavior Institute)

Administrative Titles

  • Co-Director, Stavros Niarchos Foundation (SNF) Center for Precision Psychiatry & Mental Health

Gender

  • Male

Credentials & Experience

Education & Training

  • MD, School of Medicine, National and Kapodistrian University of Athens, Greece
  • PhD, Molecular Biology, Harvard University

Honors & Awards

  • 2026: Lieber Prize for Outstanding Achievement in Schizophrenia Research, Brain & Behavior Research Foundation

Research

The Gogos lab, part of Columbia University's Stavros Niarchos Foundation (SNF) Center for Precision Psychiatry & Mental Health, investigates the biological mechanisms underlying schizophrenia and other complex psychiatric disorders, with a particular emphasis on translating human genetic discoveries and other well-characterized biological determinants of disease into mechanistic insights and potential therapeutic strategies. The laboratory studies how genetic variants and other disease-associated biological disruptions affect brain development and function, using complementary animal models and human stem cell-derived systems, including neuronal cultures and brain organoids.

An integrated, translational approach combines molecular, cellular, synaptic, electrophysiological, behavioral and advanced imaging techniques to investigate the consequences of disease-associated biological alterations across multiple levels of brain organization, from individual neurons to higher-order neural circuits and behavior. These studies aim to elucidate how distinct biological disruptions alter neuronal function and circuit organization, contribute to cognitive and behavioral impairments, and increase susceptibility to psychiatric disorders. A central goal is to identify the molecular and neural mechanisms underlying disease and uncover promising therapeutic targets.

By bridging discoveries about the biological basis of mental illness with experimental models of disease, the laboratory seeks to advance the understanding of psychiatric disorders and accelerate the translation of biological insights into new therapeutic approaches. This research is closely aligned with the broader mission of the SNF Center to advance precision psychiatry and catalyze innovation in the prevention, diagnosis and treatment of mental illness.

Research Interests

  • Models of Psychiatric Disorders
  • Neurobiology of Disease
  • Neurogenetics
  • Synapses and Circuits

Selected Publications

  1. Rao SB, Sun Z, Brundu F, Chen Y, Sun Y, Zhu H, Shprintzen RJ, Tomer R, Rabadan R, Leong KW, Markx S, Kushner SA, Xu B, Gogos JA. 2025 Aberrant pace of cortical neuron development in brain organoids from patients with 22q11.2 deletion syndrome-associated schizophrenia. Nat Commun. 16:6986.
  2. Mukai J, Cannavò E, Crabtree GW, Sun Z, Diamantopoulou A, Thakur P, Chang CY, Cai Y, Lomvardas S, Takata A, Xu B, Gogos JA. 2019 Recapitulation and Reversal of Schizophrenia-Related Phenotypes in Setd1a-Deficient Mice. Neuron 104:471-487
  3. Zaremba JD, Diamantopoulou A, Danielson NB, Grosmark AD, Kaifosh PW, Bowler JC, Liao Z, Sparks FT, Gogos JA, Losonczy A. 2017 Impaired hippocampal place cell dynamics in a mouse model of the 22q11.2 deletion. Nat Neurosci. 20:1612-1623.
  4. Hamm JP, Peterka DS, Gogos JA, Yuste R. 2017 Altered Cortical Ensembles in Mouse Models of Schizophrenia. Neuron. 94:153-167.
  5. Crabtree GW, Park AJ, Gordon JA, Gogos JA. 2016 Cytosolic Accumulation of L-Proline Disrupts GABA-Ergic Transmission through GAD Blockade. Cell Rep. 17:570-582.
  6. Tamura M, Mukai J, Gordon JA, Gogos JA. 2016 Developmental Inhibition of Gsk3 Rescues Behavioral and Neurophysiological Deficits in a Mouse Model of Schizophrenia Predisposition. Neuron. 89:1100-1109.
  7. Piskorowski RA, Nasrallah K, Diamantopoulou A, Mukai J, Hassan SI, Siegelbaum SA, Gogos JA, Chevaleyre V. 2016 Age-Dependent Specific Changes in Area CA2 of the Hippocampus and Social Memory Deficit in a Mouse Model of the 22q11.2 Deletion Syndrome. Neuron. 89:163-176.
  8. Mukai J, Tamura M, Fénelon K, Rosen AM, Spellman TJ, Kang R, MacDermott AB, Karayiorgou M, Gordon JA, Gogos JA. 2015 Molecular substrates of altered axonal growth and brain connectivity in a mouse model of schizophrenia. Neuron. 86:680-695.
  9. Takata A, Xu B, Ionita-Laza I, Roos JL, Gogos JA, Karayiorgou M. 2014 Loss-of-function variants in schizophrenia risk and SETD1A as a candidate susceptibility gene. Neuron. 82:773-780.
  10. Xu B, Hsu PK, Stark KL, Karayiorgou M, Gogos JA. 2013 Derepression of a Neuronal Inhibitor due to miRNA Dysregulation in a Schizophrenia-Related Microdeletion. Cell. 152:262-275.
  11. Xu B, Ionita-Laza I, Roos JL, Boone B, Woodrick S, Sun Y, Levy S, Gogos JA, Karayiorgou M. 2012 De novo gene mutations highlight patterns of genetic and neural complexity in schizophrenia. Nat Genet. 44:1365-1369.
  12. Sigurdsson T, Stark KL, Karayiorgou M, Gogos JA, Gordon JA. 2010 Impaired hippocampal-prefrontal synchrony in a genetic mouse model of schizophrenia. Nature. 464:763-767.
  13. Mukai J, Dhilla A, Drew LJ, Stark KL, Cao L, MacDermott AB, Karayiorgou M, Gogos JA. 2008 Palmitoylation-dependent neurodevelopmental deficits in a mouse model of 22q11 microdeletion. Nat Neurosci. 11:1302-1310.
  14. Xu B, Roos JL, Levy S, van Rensburg EJ, Gogos JA, Karayiorgou M. 2008 Strong association of de novo copy number mutations with sporadic schizophrenia. Nat Genet. 40:880-885.
  15. Stark KL, Xu B, Bagchi A, Lai WS, Liu H, Hsu R, Wan X, Pavlidis P, Mills AA, Karayiorgou M, Gogos JA. 2008 Altered brain microRNA biogenesis contributes to phenotypic deficits in a 22q11-deletion mouse model. Nat Genet. 40:751-760.
Back to top